#1 Clinical Trials Search in Europe

Anhydrous Azithromycin

This article discusses the use of Anhydrous Azithromycin in clinical trials for treating chronic lung rejection in adult patients who have undergone bilateral lung transplantation. The drug is being studied alongside belumosudil to evaluate its effectiveness in improving lung function and quality of life for transplant recipients experiencing chronic lung allograft dysfunction (CLAD).

Table of Contents

What is Anhydrous Azithromycin?

Anhydrous Azithromycin, also known as Azithromycin Anhydrous, is a medication that belongs to a class of drugs called macrolide antibiotics[1]. The term “anhydrous” means that the medication is in a form without water. Azithromycin is widely used to treat various bacterial infections, but in this context, we’ll focus on its application in lung transplant patients.

Medical Use in Lung Transplant Rejection

Azithromycin is being studied for its potential benefits in patients who have undergone lung transplantation and are experiencing a condition called chronic lung allograft dysfunction (CLAD)[1]. CLAD is a form of chronic lung transplant rejection that can occur after the transplant surgery.

In the context of lung transplant rejection, Azithromycin is used as part of a treatment regimen to help manage and potentially improve the condition of patients with CLAD. It’s important to note that while Azithromycin is being used in this setting, its exact mechanism of action in treating CLAD is still being studied[1].

How is Azithromycin Administered?

Azithromycin is administered orally, which means it is taken by mouth[1]. This makes it convenient for patients to take at home or in a clinical setting. The medication typically comes in tablet or liquid form, but the specific formulation may vary depending on the manufacturer and prescription.

Dosage Information

In the clinical trial described, patients receive Azithromycin at a dosage of at least 250 mg per day, taken at least three times a week[1]. The maximum daily dose mentioned in the trial is 250 mg. It’s crucial to understand that this dosage is specific to the trial and may not be the same for all patients or conditions. Always follow your doctor’s prescription and instructions when taking any medication.

The trial information also mentions a maximum total dose amount of 111,000 mg over a maximum treatment period of 34 weeks[1]. However, these figures are specific to the clinical trial and may not reflect typical usage outside of the study setting.

Current Clinical Trial

Azithromycin is currently being used in a clinical trial for patients with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation[1]. Here are some key points about the trial:

  • It’s a Phase 3 study, which means it’s in an advanced stage of clinical research.
  • The trial is testing the effectiveness of a drug called belumosudil in combination with Azithromycin.
  • Participants in the trial must have been taking Azithromycin for at least 8 weeks before joining the study.
  • The main goal is to see if belumosudil can improve lung function in patients with CLAD who are already taking Azithromycin.

It’s important to note that being part of a clinical trial is different from regular medical treatment. If you’re interested in participating in clinical trials, always discuss this with your healthcare provider.

Important Considerations for Patients

If you’re a lung transplant recipient or are considering using Azithromycin, here are some important points to keep in mind:

  1. Medical Supervision: Azithromycin should only be taken under the direct supervision of a healthcare professional, especially in the context of lung transplant care.
  2. Regular Monitoring: Your doctor will likely want to monitor your lung function and overall health regularly while you’re taking this medication.
  3. Side Effects: Like all medications, Azithromycin can have side effects. Discuss potential side effects with your doctor.
  4. Drug Interactions: Inform your doctor about all other medications you’re taking, as Azithromycin can interact with other drugs.
  5. Adherence: It’s crucial to take the medication exactly as prescribed. In the context of transplant care, missing doses could have serious consequences.

Remember, while this information provides a general overview of Anhydrous Azithromycin in the context of lung transplant rejection, it’s not a substitute for professional medical advice. Always consult with your transplant team or healthcare provider for personalized information and guidance.

Aspect Details
Study Type Phase 3, randomized, double-blind, placebo-controlled, parallel group
Main Objective Evaluate efficacy of belumosudil compared to placebo on lung function (FEV1) in CLAD patients
Anhydrous Azithromycin Role Background therapy, administered for at least 8 weeks before trial
Dosage ≥250 mg/day, at least 3 times a week
Maximum Treatment Period 34 weeks
Key Eligibility Criteria Adults ≥1 year post bilateral lung transplant, CLAD Stage 1 or 2, FEV1 >50% to 80% of baseline
Primary Endpoint Percent change in FEV1 from baseline to Week 26
Secondary Endpoints Changes in FVC, TLC, 6-minute walk test, quality of life measures, safety assessments

FAQ

  • What is the purpose of using Anhydrous Azithromycin in this clinical trial? Anhydrous Azithromycin is used as part of the treatment for patients with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation. It is administered for at least 8 weeks before the trial begins to help manage the condition.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults who have had a bilateral lung transplant at least one year ago, have CLAD Stage 1 or 2 with specific lung function criteria, and have been taking azithromycin for at least 8 weeks prior to the trial.
  • How is Anhydrous Azithromycin administered in the trial? Anhydrous Azithromycin is administered orally at a dose of at least 250 mg per day, taken at least 3 times a week, for a maximum treatment period of 34 weeks.
  • What are the main outcomes being measured in this trial? The primary outcome is the percent change in forced expiratory volume in 1 second (FEV1) from baseline to Week 26. Secondary outcomes include changes in lung function, exercise capacity, quality of life, and safety assessments.
  • Is Anhydrous Azithromycin being tested alone or with other medications? Anhydrous Azithromycin is being studied alongside belumosudil, which is the main drug being evaluated in this trial. The study aims to assess the effectiveness of belumosudil compared to a placebo in patients who have already been taking azithromycin.

Ongoing Clinical Trials on Anhydrous Azithromycin

  • Study on the Effectiveness of Belumosudil and Azithromycin for Adults with Chronic Lung Rejection After Lung Transplant

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

Glossary

  • Chronic Lung Allograft Dysfunction (CLAD): A condition that occurs in lung transplant recipients, characterized by a decline in lung function over time, which can lead to transplant failure.
  • Forced Expiratory Volume in 1 second (FEV1): The amount of air a person can forcefully exhale from their lungs in one second, used to measure lung function and assess the severity of CLAD.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, another measure of lung function used in the study.
  • Total Lung Capacity (TLC): The total amount of air in the lungs after taking the deepest breath possible, used to evaluate overall lung volume and function.
  • 6-minute walk test: A test that measures the distance an individual can walk on a flat surface in 6 minutes, used to assess exercise capacity and oxygen levels during activity.
  • Patient-Reported Outcomes (PROs): Information about a patient's health condition that comes directly from the patient, without interpretation by doctors or others.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it is related to the treatment.
  • Serious Adverse Events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, or cause significant disability.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-belumosudil-and-azithromycin-for-adults-with-chronic-lung-rejection-after-lung-transplant/